BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
BioXcel Therapeutics (BTAI) has scheduled its third quarter 2024 financial results release for Thursday, November 14, 2024, before U.S. financial markets open. The company will host a conference call and webcast at 8:00 AM ET the same day, featuring management's discussion of results and business updates. The webcast will be available on the company's website under the Investors & Media section, with a replay accessible for 90 days following the event.
BioXcel Therapeutics (BTAI) ha programmato il rilascio dei risultati finanziari del terzo trimestre 2024 per giovedì 14 novembre 2024, prima dell'apertura dei mercati finanziari statunitensi. L'azienda organizzerà una conference call e un webcast alle 8:00 AM ET dello stesso giorno, con una discussione dei risultati e aggiornamenti aziendali da parte della direzione. Il webcast sarà disponibile sul sito web dell'azienda nella sezione Investitori e Media, con una replica accessibile per 90 giorni dopo l'evento.
BioXcel Therapeutics (BTAI) ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 para el jueves 14 de noviembre de 2024, antes de la apertura de los mercados financieros de EE. UU. La empresa llevará a cabo una conferencia telefónica y un webcast a las 8:00 AM ET del mismo día, donde se discutirá los resultados y las actualizaciones del negocio por parte de la dirección. El webcast estará disponible en el sitio web de la empresa en la sección de Inversores y Medios, con una repetición accesible durante 90 días después del evento.
BioXcel Therapeutics (BTAI)는 2024년 11월 14일 목요일에 미국 금융 시장이 개장하기 전에 2024년 3분기 재무 결과 발표를 예정하고 있습니다. 회사는 같은 날 오전 8시 ET에 콘퍼런스 콜과 웹캐스트를 개최하며, 경영진이 결과 및 비즈니스 업데이트에 대해 논의합니다. 웹캐스트는 회사 웹사이트의 투자자 및 미디어 섹션에서 제공되며, 이벤트 이후 90일 동안 다시 볼 수 있습니다.
BioXcel Therapeutics (BTAI) a programmé la publication de ses résultats financiers pour le troisième trimestre 2024 pour jeudi 14 novembre 2024, avant l'ouverture des marchés financiers américains. La société organisera une conférence téléphonique et un webinaire le même jour à 8h00 ET, où la direction discutera des résultats et des mises à jour commerciales. Le webinaire sera disponible sur le site Internet de l'entreprise dans la section Investisseurs & Médias, avec une rediffusion accessible pendant 90 jours après l'événement.
BioXcel Therapeutics (BTAI) hat die Veröffentlichung ihrer Finanzzahlen für das dritte Quartal 2024 auf Donnerstag, den 14. November 2024 vor der Eröffnung der US-Finanzmärkte angesetzt. Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, in dem das Management die Ergebnisse und Geschäftsnachrichten bespricht. Der Webcast wird auf der Website des Unternehmens im Bereich Investoren & Medien verfügbar sein, mit einer Wiederholung, die 90 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
NEW HAVEN, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will release its third quarter 2024 financial results on Thursday, November 14, 2024, before the open of the U.S. financial markets. The Company’s management team will also host a conference call and webcast at 8:00 AM ET that day to discuss these results and provide a general business update.
| Conference Call and Webcast Details | |
| Date/Time: | Thursday, November 14, 2024, at 8:00 AM ET |
| Participant Dial-In: | 877-407-5795 / 201-689-8722 |
| The webcast link will be accessible under “News/Events” on the Investors & Media page of the Company's website at bioxceltherapeutics.com. | |
| Replay* | |
| Replay Dial-In: | 877-660-6853 / 201-612-7415 |
| Access ID: | 13749326 |
*Available for 90 days following live event
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, the date and time of the release of Company’s third quarter 2024 financial results and related conference call. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors section of the Company’s website at www.bioxceltherapeutics.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contact Information
Corporate/Investors
BioXcel Therapeutics
Erik Kopp
1.203.494.7062
Media
Russo Partners
David Schull
1.858.717.2310
Source: BioXcel Therapeutics, Inc.
FAQ
When will BioXcel Therapeutics (BTAI) release Q3 2024 earnings?
What time is BioXcel Therapeutics (BTAI) Q3 2024 earnings call?
How can I access BioXcel Therapeutics (BTAI) Q3 2024 earnings call?
